HuniLife Biotechnology, Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or companies through lice
The content above was translated by Ai
Founded Year
2013
Unified Business No.
52278884
Status
Active
Number of Employees
9
Total Paid-in
Capital
132,270,687 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious therapeutics for the treatment of human diseases while aiming to bring long lasting value to our shareholders. We are now developing new generation of novel drugs for unmet medical needs.
The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers. HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA). ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.
In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers. HuL003 is a ENO1-based ADC for oncology application.
The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers. HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA). ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.
In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers. HuL003 is a ENO1-based ADC for oncology application.
The content above was translated by Ai
